RxDoctor Payments Data

Joseph Frasca, MD

Gastroenterology · Chicago, ILNPI 1841558533

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Jazz Pharmaceuticals Inc. accounts for 76.8% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for gastroenterology clinicians in IL, where the typical reported total is $1,251.

$166in general payments, 2019–2025

Across 3 payments — averaging $55.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$127
  • Takeda Pharmaceuticals U.S.A., Inc.$25
  • Johnson & Johnson$13
$173,667in research payments, 2019–2025

Across 48 payments — averaging $3618.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$67K
  • Bristol Myers Squibb$31K
  • Boehringer Ingelheim International GmbH$25K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$19K
  • Takeda Pharmaceuticals U.S.A., Inc.$17K
  • Amgen$15K

What the payments were for

  • Food & beverage$166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$166 in reported general payments places this provider in the 15th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$38,974
Medicare patients
177
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab71$1,923,266
Humira(Cf) PenAdalimumab28$246,111
RemicadeInfliximab12$119,196
EntyvioVedolizumab13$109,706
Mesalamine26$13,018
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates51$3,352
Budesonide DrBudesonide14$1,336
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl31$468
Esomeprazole Magnesium15$455
Azathioprine14$445
Omeprazole27$401
Pantoprazole Sodium21$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$13$2,042,46183 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$25$109,70613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →